$ANVS
Annovis Bio, Inc.
XNYS•Health Care•Pharmaceutical Preparations
$0.675
▲After hours+0.90%+$0.006After hours
Annovis Bio, Inc.
XNYS•Health Care•Pharmaceutical Preparations
Flagged at $1.13 at 09:15 AM on Nov 02, then ran to $1.40 +23% that session.
The high is the session peak after our first alert, not a realized trade. Not investment advice.
Why is ANVS down today? It is at $0.675 (-44.22%), and our scanner flagged it 81 times on unusual volume this month. See the catalyst behind the move, real-time alerts the moment ANVS spikes, and full due diligence on ANVS — key stats, earnings, dilution and insider activity. Free.
Our scanner flagged $ANVS 81 times in the last 30 days. Create a free account to track $ANVS, build a watchlist, and get instant unusual-volume alerts, with a full day of premium now and 5 more when you verify your email, no card needed.
No card · 5 premium days · join 800+ traders
The top plays and unusual-volume catches our scanner flags, emailed to you. No account needed.
No spam. Unsubscribe anytime. Not investment advice.
ANVS is one of today's most active names, trading on unusually heavy volume (live price and day move above). Our scanner has fired 12 unusual-volume and momentum alerts on ANVS today, peaking at 87.9x its normal volume. Fresh from the SEC: Annovis Bio, Inc. filed an 8-K: Results of Operations, Regulation FD Disclosure, Other Material Event. A material company disclosure like this is often the real catalyst behind a move of this size.
Likely catalystPriced share offering, from an SEC filing. Read it →Across every filing on file, supply equal to 176.6% of the tradeable float is in play - 176.6% has already been sold.
One filing exceeds the whole float, which usually means our share count is stale. Check the filing directly.
Recent priced share offering — a one-time sale that has already completed (not ongoing)
42,000,000 new shares
Sources: float & market cap via Polygon · short interest via FINRA · borrow & shortability via Alpaca · SSR from Reg SHO 201 · filings & dilution via SEC EDGAR · analysts via Nasdaq.
Auto-generated from public data for research and education. Not investment advice.
| Insider | Action | Shares | % of position | Owns after | Value | Date |
|---|---|---|---|---|---|---|
Hoffman Michael B Director | Bought (open market) | +76K 0.2% of company | added 2.3% | 3.36M | $134K at $1.75 | May 20, 26 |
Hoffman Michael B Director | Bought (open market) | +714K 1.7% of company | added 28% | 3.29M | $1.5M at $2.10 | Apr 2, 26 |
Hoffman Michael B Director | Bought (open market) | +45K 0.1% of company | added 1.8% | 2.57M | $191K at $4.24 | Dec 8, 25 |
Hoffman Michael B Director | Bought (open market) | +39K 0.09% of company | added 1.6% | 2.52M | $151K at $3.85 | Nov 24, 25 |
Hoffman Michael B Director | Bought (open market) | +20K 0.05% of company | added 0.8% | 2.49M | $70K at $3.49 | Nov 21, 25 |
Hoffman Michael B Director | Bought (open market) | +15K 0.04% of company | added 0.6% | 2.47M | $32K at $2.11 | Nov 14, 25 |
Hoffman Michael B Director | Bought (open market) | +976K 2.3% of company | added 66% | 2.46M | $2.0M at $2.05 | Oct 28, 25 |
Maccecchini Maria-Luisa Officer | Bought (open market) | +98K 0.2% of company | added 8.8% | 1.21M | $200K at $2.05 | Oct 28, 25 |
Bruck Claudine Director | Other | 7K 0.02% of company | added 100% | 14K | $1000 at $0.140 | Sep 10, 25 |
Hoffman Michael B Director | Acquired (grant/award) | +15K 0.04% of company | added 1.0% | 1.48M | $34K at $2.28 | Aug 29, 25 |
Hoffman Michael B Director | Acquired (grant/award) | +19K 0.04% of company | added 1.3% | 1.46M | $48K at $2.57 | Aug 19, 25 |
Walsh Andrew Officer | Acquired (grant/award) | +500 | n/a | 500 | $1K at $2.90 | Jun 16, 25 |
Recent Form-4 filings via Nasdaq. Open-market buys are the signal worth watching. Grants and automatic (10b5-1) sells are routine. “% of position” is the share of that insider’s own holding the trade moved. Not investment advice.
Blend of news sentiment, today’s move, and community votes. Not investment advice.
News, unusual-volume alerts, AI-trader trades and community chatter - the whole story, newest first.
The tickers our scanner is lighting up most over the last 48 hours.
Comparable names in pharmaceutical preparations, closest in size first.
ANVS is one of today's most active names, trading on unusually heavy volume (live price and day move above). Our scanner has fired 12 unusual-volume and momentum alerts on ANVS today, peaking at 87.9x its normal volume. Fresh from the SEC: Annovis Bio, Inc. filed an 8-K: Results of Operations, Regulation FD Disclosure, Other Material Event. A material company disclosure like this is often the real catalyst behind a move of this size.
ANVS last traded at $0.675, down 44.22% on the day. The price and chart above update live during market hours (4 AM to 8 PM ET).
Annovis Bio, Inc. (ANVS) is next expected to report earnings on Wednesday, November 11, 2026, about 6 days away. Earnings reports often cause large overnight gaps, so many traders manage risk around the date. The date can shift until the company officially confirms it.
The ANVS Live Alerts panel on this page streams real-time unusual volume (RVOL), momentum, halt and 200-EMA alerts from our scanner the moment they fire. Our scanner has flagged ANVS 81 times in the last 30 days.
ANVS (Annovis Bio, Inc.) trades on XNYS, with a market cap of about $29M in the Pharmaceutical Preparations sector.
That depends on your strategy and risk. Day traders look for volume, volatility and a clear trend. Use the live chart, RVOL alerts and 200-EMA context on this page to judge ANVS for yourself. This is not investment advice.
Live data from TheDesperateTrader scanner. Not investment advice.
$ANVS discussion
Sign in to ask a question or join the discussion.